Pirtobrutinib for older or frail patients with mantle cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new oral drug, pirtobrutinib, for mantle cell lymphoma in patients who are 70 or older or not healthy enough for standard chemotherapy. The goal is to see if it works well with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 70 years or older
- You have mantle cell lymphoma that hasn't been treated before and needs treatment
- You are not well enough for standard full-dose chemotherapy (because of age or health problems)
- You can take pills by mouth
- You have a life expectancy of more than 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two medications, pirtobrutinib and rituximab, for people newly diagnosed with low- or medium-risk mantle cell lymphoma. It aims to see if this approach is effective and safe without needing chemotherapy.
This study tests a combination of two drugs—glofitamab (given as an infusion) and pirtobrutinib (a pill)—for people with mantle cell lymphoma that has come back or not responded to previous treatment. The goal is to see if the combo works better than either drug alone.
This Phase 2 trial tests how well the combination of pirtobrutinib and venetoclax works for people with mantle cell lymphoma that has come back or did not respond to treatment. It’s meant to help shrink the lymphoma and improve outcomes after prior therapies.
This Phase 2 trial tests how well two anti-cancer medicines—glofitamab and pirtobrutinib—work for mantle cell lymphoma (MCL) that has not responded well to prior BTK inhibitor therapy. It may help by shrinking the lymphoma after earlier treatment and checking how safe the combination is for people with similar disease history.
This trial tests a new combination of drugs (orelabrutinib plus BR) compared to BR alone for people with newly diagnosed mantle cell lymphoma who have not had treatment before. It may be an option if you are older or not able to have a stem cell transplant.
This trial tests whether adding the targeted drug zanubrutinib to standard chemotherapy (R-CHOP or R-DHAP) helps people with untreated mantle cell lymphoma. It is for adults up to age 70 who are healthy enough for intensive treatment.
Hear when a new Mantle Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.